Krah D L, Provost P J, Ellis R W
Department of Virus and Cell Biology, Merck Research Laboratories, West Point, PA 19486, USA.
J Virol Methods. 1995 Jun;53(2-3):176-87. doi: 10.1016/0166-0934(95)00013-k.
An enhanced neutralization assay was developed to permit the sensitive, specific, and reproducible measurement of antibodies to varicella-zoster virus (VZV). Optimal neutralization was achieved using a combination of guinea pig complement (C') and rabbit anti-human IgG. This provided 625-, 160- and 13- to 64-fold increases in dilution endpoints of human post-zoster serum, varicella-zoster immune globulin and representative sera from recipients of live attenuated varicella vaccine, respectively, above those measured in the absence of C' and anti-IgG. The specificity of the assay was shown by the absorption of serum neutralization capacity with VZV-specific antigen and the lack of concordance between antibody titers to VZV with those to either herpes simplex virus type-2 or cytomegalovirus. The antibody status of recipients of live attenuated varicella vaccine was established from the amount of neutralizing activity produced at a single optimal serum dilution.
开发了一种增强中和试验，以实现对水痘带状疱疹病毒（VZV）抗体的灵敏、特异且可重复的测量。使用豚鼠补体（C'）和兔抗人IgG的组合可实现最佳中和效果。这分别使带状疱疹后血清、水痘带状疱疹免疫球蛋白和减毒活水痘疫苗接种者的代表性血清的稀释终点比在无C'和抗IgG情况下测量的值提高了625倍、160倍以及13至64倍。通过用VZV特异性抗原吸收血清中和能力以及对VZV的抗体滴度与对单纯疱疹病毒2型或巨细胞病毒的抗体滴度之间缺乏一致性，证明了该试验的特异性。减毒活水痘疫苗接种者的抗体状态是根据在单一最佳血清稀释度下产生的中和活性量来确定的。
